anticancer/kansè

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 8438 rezilta yo

TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

GEN-104 is an open-label, multi-center, Phase 1/2 study evaluating quaratusugene ozeplasmid (GPX-001) plus osimertinib versus monotherapy osimertinib in patients with advanced metastatic or recurrent Non-small Cell Lung Cancer. Toxicities will be assessed by the Investigator using United States

Potentiation of Chemotherapy in Brain Tumors by Zinc

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We propose a single arm phase II clinical trial in 30 newly diagnosed GBM patients who will be treated with the standard chemo-radiotherapy with the addition of daily zinc. We will follow the toxicity, Progression free survival and overall survival of this group of patients. We hope to demonstrate

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This single-center, single-arm, open-label trial will include 89 patients with stage II-III triple-positive breast cancer (Simon's two-stage design). After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and

RAPA-501-Allo Off-the-Shelf Therapy of COVID-19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The first-in-human Phase I study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with post-intubation, stage 3 COVID-19 disease, with key endpoints of safety, biologic and potential disease-modifying effects. The randomized, double-blind, placebo-controlled

Prospective Breast Cancer Biobanking

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A. Early detection of systemic relapses in breast cancer. WP 1. Analysis of primary tumor. Analysis of primary tumor and metastases (Pathology group). In this work package both DNA and RNA from the primary tumors of 125 high-risk (Luminal-B) patients will be analyzed by next-generation sequencing

Completely Abdominal Approach Laparoscopic Partial Intersphincteric Resection for Rectal Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with cT1 to cT2 low rectal cancer are directly operated through completely abdominal approach laparoscopic partial ISR surgery. Patients with cT3 low rectal cancer are firstly treated with standard neoadjuvant chemoradiotherapy until down staged to ycT1 to ycT2. The postoperatively

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This multi-center, phase II study will be conducted in two parts and assess the clinical benefit, safety, pharmacokinetics, and pharmacodynamics of ulixertinib (BVD-523) in patients with advanced malignancies. Part A (tumor histology agnostic) will be open label and enroll patients to one of six

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts. During Part I, dose escalation part of the

Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Non-small cell lung cancer (NSCLC) is the most common histological form, accounting for 85% of all bronchopulmonary cancers (PBC). The advent of Immunity Checkpoint Inhibitors (ICIs) targeting Programmed cell Death-1 (PD-1) is changing current treatment algorithms. Preliminary results from work

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Breast cancer has been one of the most common malignant tumors in women, accounting for 23% of all the malignancies. There are estimated 1,300,000 new cases of breast cancers and 400,000 deaths due to breast cancers every year in the world. Hormone receptor-positive breast cancer accounts for about

Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The screenings for the next 2 decades indicate an exponential increase in the incidence of neoplastic diseases in the elderly population. In order to successfully balance effectiveness and low toxicity of immunochemotherapy, a treatment personalisation based on an objective evaluation of fitness is

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This prospective, single-arm phase 2 clinical trial is looking at whether gentle skin care, sun protection and dilute bleach baths might decrease the chances or the severity of skin changes that occur during treatment for brain tumors. The research study procedures include screening for eligibility

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye